戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ckers (atenolol, metoprolol, propranolol, or nadolol).
2  are beta3-sparing, including propranolol or nadolol.
3 receiving metoprolol compared to propranolol/nadolol.
4  contractility with and without atropine and nadolol.
5        Thirty-five infants were treated with nadolol.
6 eatment with the beta-adrenergic antagonist, nadolol (0.5 mg/kg), but not by the alpha-antagonist phe
7 Propranolol (10 mg/kg, intraperitoneally) or nadolol (10 mg/kg, intraperitoneally) administered 30 mi
8 with metoprolol (a beta(1)-AR antagonist) or nadolol (a beta(1)- and beta(2)-AR antagonist), but were
9 ed group, acute responders were treated with nadolol and acute nonresponders with nadolol+nitrates.
10 ed 5-7 days after maximal tolerated doses of nadolol and nitrates.
11 rker and racemic mixtures of the antagonists nadolol and propranolol demonstrated that the immobilize
12 ptor blockers (specifically, propranolol and nadolol) and sodium and transient outward current blocke
13                              Propranolol and nadolol are equally effective, whereas symptomatic patie
14 lution was 2.4 (95% CI, 0.5-4.4) higher with nadolol compared with propranolol.
15 shortening effect compared to metoprolol and nadolol, especially in patients with prolonged QTc.
16 (95% CI, 7.2-30.0) for color in favor of the nadolol group, demonstrating that nadolol was noninferio
17                         Oral propranolol and nadolol in escalating doses up to 2 mg/kg/d.
18 rity margin of 10% compared propranolol with nadolol in infants aged 1 to 6 months with problematic I
19 d trial of endoscopic variceal ligation plus nadolol in preventing recurrent variceal bleeding and se
20 other less lipophilic beta-blockers, such as nadolol, may be preferable in individuals who experience
21 ranolol (n = 134), metoprolol (n = 147), and nadolol (n = 101) were analyzed, excluding patients <1 y
22           The control group was treated with nadolol+nitrates+ligation.
23 ed with nadolol and acute nonresponders with nadolol+nitrates.
24                  (ii) Chronic treatment with nadolol or carvedilol significantly increased beta-AR de
25 e observed that: (i) The beta-AR antagonists nadolol or carvedilol, given as a single i.v. injection
26 evented by addition of the betaAR antagonist nadolol or exogenous IFN-gamma.
27 renergic receptor antagonists propranolol or nadolol or the alpha1- + beta1,2,3-adrenergic receptor a
28  at 1-3 months of treatment with propranolol/nadolol plus endoscopic band ligation.
29               Chronic nonresponders received nadolol+prazosin and had a third HVPG study.
30 ilar among the 4 beta-blockers, but in LQT2, nadolol provided the only significant risk reduction (ha
31 of Nb80 binding in assisting displacement of nadolol to isoprenaline.
32 ndicates a good prognosis during propranolol/nadolol treatment but requires two HVPG measurements.
33                                         Oral nadolol was noninferior to oral propranolol, indicating
34 vor of the nadolol group, demonstrating that nadolol was noninferior to propranolol.
35 n LQTS, their efficacy differed by genotype; nadolol was the only beta-blocker associated with a sign
36 s for atenolol, metoprolol, propranolol, and nadolol were 0.71 (0.50 to 1.01), 0.70 (0.43 to 1.15) 0.